Remove Clinical Development Remove Information Remove Structure Based Drug Design (SBDD)
article thumbnail

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

The Pharma Data

For more information, please visit [link]. Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. For more information, please visit www.metrionbiosciences.com. . TOKYO and CAMBRIDGE, England , Feb. About Metrion Biosciences. View original content: [link].

article thumbnail

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

The Pharma Data

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. For more information, please visit [link].

article thumbnail

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

The Pharma Data

A further aim of the collaboration is to generate high resolution structural information around the GPCR-E3 ligase complex to enhance drug discovery efforts as well as provide proof of concept for targeted degradation discovery approaches with other GPCRs and other target classes. For more information, please visit [link].